FDA’s Activism Changes the Landscape In Treatment, Trials of Squamous NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Citing a dramatic improvement in overall survival in second-line squamous non-small cell lung cancer, FDA rapidly approved the Bristol-Myers Squibb drug Opdivo (nivolumab).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login